Monkeypox – City of Toronto Vaccination Clinics
as “Smallpox and other Orthopoxviruses including Monkeypox” under the Health Protection and Promotion Act (HPPA)
Monkeypox Vaccine (Imvamune®) Guidance for Health Care Providers
Version 1.0 – June 14, 2022
This guidance provides basic information only. This document is not intended to provide or take the place of medical advice, diagnosis or treatment, or legal advice. Ontario continues to monitor for cases of monkeypox and is working collaboratively with health care providers, Public Health Ontario (PHO) and the Public Health Agency of Canada (PHAC) to address health risk(s). New guidance will continue to emerge as new information becomes available and the epidemiology of this situation evolves. Read More…
Monkeypox Vaccine Information Sheet
Q&A for Monkeypox
Interim Vaccine Guidance for Post-Exposure Prophylaxis (PEP) and How to Access to Tecovirimat
Version 1.0 – May 28, 2022
Monkeypox is a rare disease that is caused by infection with the monkeypox virus. The monkeypox virus belongs to the Orthopoxvirus genus which also includes the variola virus (which causes smallpox) and the vaccinia virus (used in smallpox vaccine). Monkeypox is usually a mild and self-limiting disease, and most people recover within 2 to 4 weeks. However, severe illness can occur in some people.
Ontario continues to monitor for cases of monkeypox and is working collaboratively with health care providers, Public Health Ontario (PHO) and the Public Health Agency of Canada (PHAC) to address health risk(s). Given that the situation is rapidly evolving, the following are interim recommendations on the use of vaccination for post-exposure prophylaxis of select contacts, and information on how to access Tecovirimat (TPoxx®) for the treatment
of severe monkeypox infection.